Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 39Nausea 31Neoplasms 10Breast Neoplasms 10Lymphoma 9Multiple Myeloma 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 6Sezary Syndrome 4Myeloproliferative Disorders 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Pruritus 3Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Aprepitant × Clear all
NCT01450826 2018-06-26

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Duke University

Phase 2 Completed
136 enrolled 10 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡